Literature DB >> 10090846

TGF-beta2 activates proliferative scar fibroblasts.

P Smith1, G Mosiello, L Deluca, F Ko, S Maggi, M C Robson.   

Abstract

BACKGROUND: Cytokines, such as the transforming growth factor beta (TGF-beta) isoforms, have been linked to the formation of proliferative scars. This study examines the stimulating effects of exogenous TGF-beta2 on cultured keloid, burn hypertrophic scar, and normal skin fibroblasts and whether such effects can be suppressed with TGF-beta2 antibody.
METHODS: In vitro, the fibroblast-populated collagen lattice (FPCL) is used in the evaluation of fibroblast activation by measuring contraction of the lattice over time. Primary cultures of fibroblasts were grown from keloids, burn hypertrophic scars, and normal skin using standard cell culture techniques. TGF-beta2 (10 ng/ml) was added to each of the three types of cell cultures and placed on prefabricated FPCLs. Each was tested against their normal control counterparts. TGF-beta2 antibody (100 ng/ml) was then placed on the TGF-beta2-treated FPCLs. All lattices were allowed to contract and areas were measured for 5 days.
RESULTS: Compared to controls, keloid fibroblasts were most affected by the addition of exogenous TGF-beta2. Normal skin fibroblasts did not show a significant increase in contraction early on, yet a significant difference was seen as time progressed. The addition of TGF-beta2 antibody inhibited the function of keloid and burn hypertrophic scar fibroblasts. It also reversed the increased contraction of the TFG-beta2-treated proliferative scar fibroblasts.
CONCLUSION: By utilizing an in vitro model, we have demonstrated that TGF-beta2 antibody reverses the increased contraction of FPCLs by proliferative scar fibroblasts treated with TGF-beta2. This points to a possible treatment modality in patients afflicted with this disfiguring problem. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10090846     DOI: 10.1006/jsre.1999.5580

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  7 in total

1.  Sequential cytokine therapy for pressure ulcers: clinical and mechanistic response.

Authors:  M C Robson; D P Hill; P D Smith; X Wang; K Meyer-Siegler; F Ko; J S VandeBerg; W G Payne; D Ochs; L E Robson
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

2.  Transplantation of fetal instead of adult fibroblasts reduces the probability of ectopic ossification during tendon repair.

Authors:  Zhi Fang; Ting Zhu; Wei Liang Shen; Qiao Mei Tang; Jia Lin Chen; Zi Yin; Jun Feng Ji; Boon Chin Heng; Hong Wei Ouyang; Xiao Chen
Journal:  Tissue Eng Part A       Date:  2014-05-15       Impact factor: 3.845

Review 3.  The evidence for the role of transforming growth factor-beta in the formation of abnormal scarring.

Authors:  Richard L Chalmers
Journal:  Int Wound J       Date:  2011-03-30       Impact factor: 3.315

4.  Keloid-derived fibroblasts are refractory to Fas-mediated apoptosis and neutralization of autocrine transforming growth factor-beta1 can abrogate this resistance.

Authors:  T Chodon; T Sugihara; H H Igawa; E Funayama; H Furukawa
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

5.  Characterization of human vocal fold fibroblasts derived from chronic scar.

Authors:  Marie E Jetté; Supriya D Hayer; Susan L Thibeault
Journal:  Laryngoscope       Date:  2013-03       Impact factor: 3.325

Review 6.  Hypertrophic scars and keloids: Overview of the evidence and practical guide for differentiating between these abnormal scars.

Authors:  Grace C Limandjaja; Frank B Niessen; Rik J Scheper; Susan Gibbs
Journal:  Exp Dermatol       Date:  2020-07-06       Impact factor: 3.960

7.  Enhanced Dupuytren's disease fibroblast populated collagen lattice contraction is independent of endogenous active TGF-beta2.

Authors:  Raymond Tse; Jeffrey Howard; Yan Wu; Bing Siang Gan
Journal:  BMC Musculoskelet Disord       Date:  2004-11-12       Impact factor: 2.362

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.